Xencor and Adlai Nortye add new oncology data as ESMO roundup widens
Xencor reported Phase 1 XmAb819 results in kidney cancer and Adlai Nortye set an AN4035 presentation, joining earlier Nanobiotix, NovaBridge and Eikon ESMO updates.
SEC filing (5)
3 stories
Xencor reported Phase 1 XmAb819 results in kidney cancer and Adlai Nortye set an AN4035 presentation, joining earlier Nanobiotix, NovaBridge and Eikon ESMO updates.
SEC filing (5)
Christ, former Immatics CFO, takes over October 1, 2026, replacing Bart Van Rhijn after his five-year tenure at the company.
SEC filing
New Phase 1 lung cancer data, early CONVERGE efficacy signals, and a NANORAY-312 protocol amendment accompanied a first half 2026 financial report showing €110.9 million in cash.
SEC filing